Study S001091

Efficacy and Safety of iGlarLixi Versus Standard of Care in a Real-world Adult China Population With Uncontrolled Type 2 Diabetes on Oral Agents-a Pragmatic Randomized Controlled Trial

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT07307235
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE4
Masking: NONE
Status: RECRUITING
Enrollment: 1316
Start: 2025-12-13
Primary completion: 2027-06-30
Lead sponsor: Shanghai Zhongshan Hospital
Conditions: Type 2 Diabetes
Interventions: DRUG:iGlarLixi (insulin glargine/lixisenatide); DRUG:standard of care (basal insulin or premixed insulin, excluding any GLP-1 receptor agonist-containing drugs)
Results posted: FALSE

Registered primary outcomes

hemoglobin A1c (HbA1c) change [from baseline to week 24]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.